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Abstract:  1 
 2 
The European Paediatric Formulation Initiative (EuPFI), founded in 2007, aims to 3 
promote and facilitate the preparation of better and safe medicines for children 4 
through linking research, and information dissemination. It brings together the 5 
capabilities of industry, academics, hospitals and regulators within a common 6 
platform in order to scope the solid understanding of the major issues, which will 7 
underpin the progress towards the future of paediatric medicines we want.  8 
The EuPFI was formed in parallel to the adoption of regulations within the EU and 9 
USA and has served as a community that drives research and dissemination through 10 
publications and the organisation of annual conferences. The membership and reach 11 
of this group has grown since its inception in 2007 and continues to develop and 12 
evolve to meet the continuing needs and ambitions of research into and 13 
development of age appropriate medicines. Five diverse workstreams (Age-14 
appropriate medicines, Biopharmaceutics, Administration Devices, Excipients and 15 
Taste Assessment & Taste Masking (TATM)) direct specific workpackages on behalf 16 
of the EuPFI.  Furthermore EuPFI interacts with multiple diverse professional groups 17 
across the globe to ensure efficient working in the area of paediatric medicines. 18 
Strong commitment and active involvement of all EuPFI stakeholders has proved to 19 
be vital to effectively address knowledge gaps related to paediatric medicines, 20 
discuss potential areas for further research and identify issues that need more 21 
attention and analysis in the future. 22 
 23 
Abstract
Introduction 1 
 2 
The importance of developing safe and effective medicines for children has now 3 
been recognised. It has resulted in a paradigm shift in the profile of and the 4 
expectations for research with paediatric populations including policy changes in the 5 
global medicines environment. Regulations in both Europe and the USA mandate the 6 
development of paediatric medicines for new products of drugs that are still patent 7 
protected and incentives are in place for the development of off-patent paediatric 8 
medicines  ((1, 2)). The formulation of paediatric medicines can be challenging since 9 
it is necessary to consider the diversity of this patient population in terms of age 10 
with associated compliance challenges such as acceptable palatability and potential 11 
safety concerns associated with excipients. Considering the issues in paediatric 12 
product development are shared among the stakeholders (governments, regulatory 13 
authorities, research institutions, pharmaceutical industry, and healthcare 14 
professionals), an integrated and co-coordinated approach is needed to address the 15 
issues and knowledge gaps. In 2007, the European Paediatric Formulation Initiative 16 
(EuPFI) was launched with the objective of identifying the issues and challenges in 17 
paediatric drug formulation development. This article provides an overview of the 18 
EuPFI consortium, highlighting the activities and efforts invested by EuPFI members. 19 
It also presents the challenges faced by the group members to advance and promote 20 
development of better medicines for the paediatric population.  21 
 22 
EuPFI Background 23 
 24 
Creation of the EuPFI consortium has been a major achievement in itself. EuPFI was 25 
created informally in 2007 based on the genuine willingness of formulation 26 
scientists’ aspiration to work together to in a non-competitive environment to 27 
understand better and learn how formulation research and development could 28 
better fulfill the needs of sick children. It evolved quickly into a structured 29 
established consortium with a mission to promote and facilitate the development of 30 
better and safe medicines for children through linking research and information 31 
dissemination. Seven founding members (GlaxoSmithKline, Novartis, Roche, 32 
Manuscript Body
University College London, AstraZeneca, Boeringer Ingelheim and MSD) raised 33 
sufficient funds to support the initial development of the EuPFI infrastructure. Since 34 
then much has been achieved; aims have evolved and are more refined, more 35 
specific and ambitious. Today, EuPFI is a consortium of 10 pharmaceutical 36 
companies, 5 universities, 1 hospital and uniquely, the European Medicines Agency 37 
(EMA) as an observer. Table 1 provides the goals and objectives of EuPFI consortium.  38 
 39 
EuPFI Framework 40 
To enhance collaboration and build competencies, several membership options and 41 
criteria were defined (Associate, Sponsor and Observer) [Figure 1]. EMA acts as an 42 
observer to the group to observe proceedings/discussions in a passive way. They 43 
contribute to the exchange of comments and understanding of any 44 
recommendations raised by group members but does not influence the objectives of 45 
the EuPFI. The consortium members meet regularly (usually twice a year face to face 46 
and then over teleconferences as required). From time to time, other stakeholders 47 
are invited to attend the face to face meetings and present their work to the group. 48 
For example EuPATI (European Patients’ Academy on Therapeutic Innovation) 49 
expressed interest in being part of EuPFI and was invited to provide an overview to 50 
explore how to set up a two-way collaboration as EuPFI recognise the importance of 51 
Patient and Public involvement (PPI). EuPFI has five workstreams (Figure 1) each 52 
addressing a fundamental aspect of the development of medicines for children. 53 
Information on the work of each workstream including key deliverables for the near 54 
future are listed below.  55 
 56 
Age Appropriate Formulations Workstream (AAF) 57 
Children require age appropriate formulations that can deliver variable dose with 58 
age/weight, have acceptable safety and are adapted to their development and 59 
ability to take medicines. However there is limited knowledge about the age 60 
appropriateness of different dosage forms and limited availability of appropriate 61 
dosage forms even when the medicine is authorized for children (3). To overcome 62 
age appropriate formulation-related issues, healthcare professionals, patients and 63 
parents often have to resort to pharmaceutical compounding and drug 64 
manipulations. These are risky practices that can potentially cause harm, including 65 
toxicity or therapeutic failure, with the pharmacokinetic and clinical outcome of the 66 
medication not being fully known. The workstream activities are centered around 67 
the development and evaluation of medicines for marketing authorisation and guide 68 
the use of modifications to the dosage form in practice. The intent is to provide 69 
guidance to industry, regulators and academic researchers of the age-70 
appropriateness of different pharmaceutical dosage forms.  An initial activity was 71 
therefore to consider a means by which age appropriate formulations could be 72 
selected, which requires a risk/benefit analysis on a case-by-case basis. The group 73 
proposed a structured integrated approach for assessing the risk and benefits of 74 
different pharmaceutical design options against pre-determined criteria relating to 75 
different routes of administration and formulation options including the safety of 76 
excipients, efficacy, usability, manufacturability, cost and patient access (4). 77 
Recognizing that there is confusion about the types of paediatric pharmaceutical 78 
preparation that are available for approval by medicines regulators, a reflection 79 
paper on ‘Preparation of medicines for children – a hierarchy of definition’ was 80 
published by AAF workstream members (5). The paper explores compounding and 81 
manipulation of medicines in relation to approval by medicines regulators to fulfil 82 
the needs of the individual patient. The team has proposed standardised definitions 83 
and terminology to clarify the types of paediatric pharmaceutical preparation. It 84 
aims to simplify strategies in product development to ensure quality and 85 
bioavailability. Another key aspect in development of age appropriate formulation is 86 
patient acceptability. Children and older adults differ in many aspects from the other 87 
age subsets of population and require particular considerations in medication 88 
acceptability. AAF workstream published a review highlighting the similarities and 89 
differences in the two age groups in relation to factors affecting acceptability of 90 
medicines (6) and a paper highlighting how formulation factors affect the 91 
acceptability of different oral medicines in children (7). Currently the workstream is 92 
examining the acceptability of pharmaceutical products for children, evaluating 93 
formulation attributes, methodology development and criteria for acceptability 94 
assessments.  Moreover addressing manufacturing challenges in developing 95 
paediatric formulations and proposing novel solutions e.g. for poorly water-soluble 96 
drugs is underway through publications. Future tasks include considering industrial 97 
perspectives in harmonising formulation development for adults and children and 98 
collaborating with regulatory bodies on issues of age-appropriateness of paediatric 99 
formulations. Another task would be to review the use of modified release 100 
formulations and different routes of administration in children to shift the emphasis 101 
to alternative routes which are potentially understudied  and bridge the evidence 102 
gap. 103 
  104 
Biopharmaceutics  105 
 106 
Improving the understanding of biopharmaceutical assessment of paediatric 107 
pharmaceutical products enables more efficient development of medicines designed 108 
for children due to availability of appropriate in vitro tests that de-risk clinical 109 
assessment. The workstream has reviewed in vitro tests used in adult populations to 110 
determine what amendments are required to ensure they are relevant for a 111 
paediatric population (8). Specifically research undertaken by the biopharmaceutics 112 
workstream was to identify the relevant volume to classify a dose as highly soluble; 113 
values increased with age from a volume of 25 mL being proposed for neonates 114 
compared to the adult volume of 250 mL. Dissolution conditions also suggested 115 
reduced volumes for younger children with <250mL for newborns and infants and 116 
larger volumes from 250-900mL for older children and adolescents. In addition, the 117 
applicability of the Biopharmaceutical Classification System (BCS) to paediatric 118 
populations was reviewed both using the literature (9) and from the results of a 119 
cross industry survey (10). The results of these reviews highlight several knowledge 120 
gaps in current methodologies in paediatric biopharmaceutics that are being 121 
addressed by the group. This includes better characterisation of the physiology and 122 
anatomy of the gastrointestinal tract (GI) tract in paediatric patients; 123 
characterisation of age-specific changes in drug permeation across the intestinal 124 
membrane and the development of biorelevant media and testing conditions for 125 
dissolution. 126 
 In collaboration with AAF, the current priority for the workstream is to understand 127 
the impact of co-administration of paediatric medicines with foods (such as apple 128 
sauce, pudding) that are commonly used to facilitate administration and improve 129 
compliance. There is no guidance on how the impact of manipulations is risk 130 
assessed from the laboratory to the patient. Non-standardised development 131 
approach for paediatric products increases the relative cost and timelines to support 132 
labelling claims. The Biopharm group aims to address the risk level of co-133 
administration of food with medicine on bioavailability based on a literature search 134 
and a discussion amongst experts. The group will also explore the biopharmaceutics 135 
tools used to predict food effects and evaluate how bridging may be achieved for in 136 
vitro prediction of in vivo performance in children. Future priority is to extend the 137 
understanding the biopharmaceutics of excipients, for exampler identifying how 138 
excipients can affect the absorption of drugs and GI physiology in children. 139 
 140 
Administration Devices 141 
It is undeniable that the need for and the type of paediatric administration device 142 
should be considered as an integral part of the paediatric product development 143 
process. The device should not only be technically capable of measuring the 144 
required/correct doses but also easily accessible and sufficiently user-friendly so as 145 
to facilitate compliance.  To address these issues, the devices workstream aims to 146 
identify and highlight current paediatric medicine administration devices practices 147 
and issues, with the ultimate aim of informing and facilitating the development and 148 
access to easy to use devices. 149 
The workstream has reviewed currently available paediatric administration devices 150 
(oral, pulmonary, parenteral, nasal and ocular routes) together with challenges 151 
associated with their use and recent developments (11, 12). In addition, as both the 152 
understanding and the usage of medical devices for oral and respiratory drug 153 
administration are heterogeneous among patients and caregivers, the workstream 154 
conducted a survey in hospital-based healthcare professionals (HCPs) (doctors, 155 
pharmacists and nurses) in six European countries to gain an understanding of HCP 156 
experiences of and opinions on oral and pulmonary paediatric administration 157 
devices (13). The countries selected (UK, Italy, Spain, France, Hungary and Germany) 158 
were considered to represent the geographical and cultural diversity of Europe. The 159 
survey results provided some valuable insights indicating that HCPs are aware of 160 
patients and caregivers having difficulty in using these types of devices.  The 161 
challenge for this activity was identifying and contacting  potential participants in 162 
each country since group members had no direct access to HCPs and no formal links 163 
to any hospitals or patient groups. To build upon these findings, the workstream is 164 
planning to conduct a similar survey in patients and their caregivers (parents, non-165 
HCPs) to help identify areas for improvement. Long-term activities of the 166 
workstream include the development of guidance for conducting user handling 167 
studies, and an investigation into industry knowledge gaps for the development of 168 
administration devices and combination products, including regulatory 169 
requirements.  170 
 171 
Excipients 172 
 173 
One critical element in the development of paediatric formulations is the selection 174 
and use of excipients, as their safety in paediatric subpopulations is often unknown.  175 
There are many issues (diseases specific, idiosyncratic reactions, physiological 176 
limitation) that have to be considered in the excipients selection process. Some 177 
excipients (e.g. propylene glycol, benzyl alcohol) are known to be less well tolerated 178 
by children depending upon the administration route, especially neonates and young 179 
children whose physiological system are still developing. Since excipients may be 180 
toxic, focused and detailed research is urgently needed to identify and support the 181 
use of excipients in different subsets of the paediatric population. Even though the 182 
demand for paediatric data on the safety of excipients has grown considerably, there 183 
is very limited paediatric excipient safety data in the public domain, and it is 184 
distributed throughout many sources. In an effort to address these availability and 185 
accessibility issues, the excipients workstream has worked in collaboration with 186 
other networks such as United States Paediatric Formulation Initiative (USPFI) and 187 
Global Research in Paediatrics (GRiP) to develop the Safety and Toxicity of Excipients 188 
(STEP) database (14). This user-designed resource compiles the clinical, non-clinical, 189 
in-vitro, review and regulatory information of excipients into one freely accessible 190 
source. The database  assists in screening and selecting of excipients for use in 191 
children and thus facilitates paediatric drug development (15). STEP launched in 192 
October 2014 and now has information on 40 excipients with users from industry, 193 
academics, hospitals and regulators. It is accessible freely from EuPFI website and 194 
perceived as useful and an important addition to current resources (16). Existing 195 
data is updated regularly and additional excipients are added quarterly.  It is 196 
important to focus on the future by moving forward with the addition of excipients 197 
and enriching the existing content for the continuation of the use of the STEP 198 
database. Hence “Sponsor an Excipient” scheme has been introduced. The scheme 199 
allows end-users to include the excipients of their choice in the STEP database at 200 
minimal costs.  201 
 202 
Taste Assessment & Taste Masking (TATM) 203 
 204 
Improving the understanding of taste assessment tools and methodology used 205 
during the development of pharmaceutical products designed for paediatric 206 
populations is a must in parallel with better understanding of taste masking 207 
strategies that lead to the development of paediatric pharmaceutical products that 208 
have an acceptable taste.  The first inter-laboratory testing of electronic taste 209 
sensing systems was led by EuPFI (five participating centers including 3 EuPFI 210 
members), each working with the Insent (Insent Inc., Atsugi-Shi, Japan) e-tongue 211 
(17). Most of the published data reported good correlation between the human 212 
taste panel test and the electronic taste sensing systems. However, in most of these 213 
studies methods followed for bitterness prediction and constructing the correlation 214 
with human taste data were not always fully described. Electronic sensors give a 215 
relative taste statement and should be validated with human taste panel tests. 216 
Ideally electronic tongues could be used for early screening of taste of pure APIs and 217 
optimisation of taste masked preclinical formulations in industry. 218 
However until it is demonstrated that electronic tongues can reliably predict 219 
bitterness intensity of the compounds, which were not used for developing 220 
calibration model, the use of this technology is still limited. A review paper to 221 
provide an overview of different approaches to taste masking APIs in paediatric oral 222 
dosage forms, with a focus on the tolerability of excipients used was also published 223 
(18) (19). Currently TATM workstream focuses on 1) consolidating “Electronic tongue 224 
“user group, 2) the application of non-human in vivo, in silico and cell based taste 225 
assessment tools in pharmaceutical taste assessment. 226 
 227 
Reflection and challenges 228 
Nine years after its initiation, EuPFI is a well-established collaboration of academia, 229 
industry, hospital and regulatory authorities, formed to harness the energies of 230 
these stakeholder groups for their common purpose and most importantly to 231 
provide the drive for finding solutions to issues in paediatric drug development. One 232 
of the strengths of the consortium has been its association with EMA, as observer on 233 
the group. The EMA representative participates in the consortium meetings and the 234 
group works together to update the research, identify gaps and discuss the 235 
regulatory needs and implications for paediatric product development. EuPFI 236 
members are invited to represent the group at several external meetings including 237 
EMA workshops. The annual conferences organised by EuPFI offers the opportunity 238 
for paediatric formulation specialists to exchange ideas and present recent 239 
accomplishments as well as discuss remaining challenges for the future with a vision 240 
of better medicines for children. So far the consortium has organized 7 annual 241 
conferences with up to 200 participants at a time. The 8th annual conference is 242 
scheduled for 21st and 22nd Sept 2016 in Lisbon, Portugal (http://www.eupfi.org/8th-243 
conference/). The proceedings and selected invited articles are published in a special 244 
issue of International journal of pharmaceutics following each conference (20-26). 245 
The collaborative effort has resulted in significant progress to date and the 246 
identification of new challenges to be met. However the process has not been a 247 
smooth journey and success has been achieved  through developing partnerships 248 
and collaboration.  249 
 250 
Shared vision and consortium management 251 
Given the diversity of approaches to the development of paediatric formulations, 252 
consortium members worked to develop a shared vision. This is a long term and 253 
evolving process. As new members joined the consortium, the agenda of various 254 
stakeholders (patients, academia, clinicians, industry and policy makers) differed, 255 
and was sometimes difficult to reconcile. Maintaining a shared vision is a challenge 256 
as is keeping the group  small and manageable. Due to the complexity of managing 257 
larger organizations, the consortium members preferred to restrict EuPFI  to 20- 25 258 
core members. It was also agreed that, at least initially, EuPFI would be limited to 259 
Europe. However, later due to large interest from other countries such as India and 260 
US, it was decided to accept  members from other countries, but only if they were 261 
able to participate at face-to-face meetings held twice in a year. The success of the 262 
consortium has been to achieve a balance between the shared vision of the 263 
consortium, added value of each member and the specific aims of each workstream.  264 
 265 
Potential overlap between networks 266 
Considering the large number of networks that have been established since the 267 
implementation of paediatric regulations and which are currently flourishing globally 268 
(Turner) such as GRiP, USPFI, some overlap between their activities is inevitable. 269 
Obviously, this might result in duplication of efforts and dissipation of resources.  270 
Within EuPFI emphasis is placed on establishing links and synergies in order to  avoid  271 
duplication of work and indeed encourage harmonization.  In 2014, EuPFI in 272 
collaboration with Pediatric Formulation Working Group of the Innovative and 273 
Quality (IQ) Consortium (PFWGIQ) conducted a systematic survey of researchers and 274 
regulators on current practices in paediatric product development (http://www.grip-275 
network.org/index.php/en/news/item/57). ‘GRiP’ is an initiative funded by the 276 
European Union Seventh Framework Programme (FP7/2007-2013) to stimulate and 277 
facilitate the development and safe use of medicines in children through 278 
development of a comprehensive training programme and integrated use of existing 279 
research capacity. EuPFI members contributed to the paediatric formulation module 280 
of the GRiP e-Master of Science in Paediatric Medicines Development and Evaluation 281 
and were also actively involved in delivering ‘Meet the Expert in Paediatric 282 
Formulations’ webinars series (http://www.grip-283 
network.org/index.php/cms/en/Webinars - top). GRiP has partially funded the 284 
development, quality control and validation of the STEP database, which is 285 
developed in collaboration with USPFI. The USPFI was formed as a project of the 286 
Eunice Kennedy Shriver National Institute of Child Health and Human Development 287 
(NICHD) in 2005 to identify the issues and challenges in developing formulations for 288 
children. (27). As both EuPFI and USPFI groups were working on similar issues, it was 289 
decided to join the forces in the development of the STEP database.  The EuPFI 290 
excipients workstream worked with USPFI in collecting the information needs of the 291 
potential users and evaluating the need for the STEP database. USPFI also 292 
contributed to the development of methodologies for data collection, performing 293 
the usability study of the STEP database and continues to contribute via performing 294 
the searches on the additional excipients to be included in the database as part of 295 
the database expansion. Additionally, there is some overlap between EuPFI 296 
membership and the SPaeDD-UK project (Smart Paediatric Drug Development – UK, 297 
accelerating paediatric formulation development 298 
http://www.paediatricscienceuk.com),  funded by Innovate UK which aims to generate 299 
a structured approach to designing age-appropriate medicines for children and 300 
technology for predicting their quality and performance (28).  301 
In addition, a first transatlantic workshop on paediatric formulation development is 302 
organised through M-CERSI (University of Maryland's Center of Excellence in 303 
Regulatory Science and Innovation funded by the FDA as a collaborative partnership 304 
between University of Maryland and FDA) and held in US in June 2016. It aims to 305 
provide an opportunity for experts to share their experiences and move towards 306 
consensus regarding best practices for developing age-appropriate drug products, 307 
which meet the needs of pediatric patients aligned with the requirements of 308 
regulatory agencies.  309 
 310 
Sustainability of the consortium 311 
There is the clear commitment of all partners to work together, to combine their 312 
expertise and strength, and to create a critical mass that is well integrated in the 313 
European pediatric formulation research area. However, unless stable funding can 314 
be secured, sustaining a consortium is truly challenging and future options are being 315 
explored. For example, the excipients workstream has recently launched the 316 
“sponsor an excipient” campaign. It will help finance excipients that have not yet 317 
been reviewed under the STEP database project and will help expedite the data 318 
curation process and maintain the database.  319 
 320 
Member’s commitment 321 
Maintaining a balance between the interests of members and their day-to-day 322 
responsibilities is another challenge. The consortium  depends heavily on the time 323 
and commitment of the members who often have conflicting priorities and hence  324 
generally work on EuPFI activities in their own time. To date the support from the 325 
EuPFI members to formulating innovative ideas to issues in paediatric formulation 326 
development is what has kept the consortium active.   327 
 328 
Concluding remarks 329 
 330 
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Reviewer's comments 
This paper is a review of the EuPFI consortium and their work, structure and focus. 
It gives valuable information on EuPFI and the significant contribution this initiative 
is making. Being a European initiative, it is important to flag this work worldwide, so 
also to the readers of AAPS PharmSciTech, in particular considering the significant 
global focus of EuPFI's work and their collaborative approach. 
It is my understanding that the authors have been invited for this manuscript, and as 
such, the intended focus and scope is likely clearly communicated between the 
editor/guest editors/journal and the authors. 
 
Reviewer 1 
 
Comment 1: 
The structure of the manuscript is built on the historical context, the main focus 
areas (workstreams), and the way the consortium is working. The paper may give the 
impression being in a 'report' format, listing aims, tasks and achievements. In this 
context, some more reflections could have added value. In particular, it would have 
been interesting to include some reflections on the challenges they have 
experienced during these years of comprehensive work, considering the complexity 
of this task. Also, some more specific practical examples would have shed further 
light on the importance of their work, concretizing the issues highlighted in the 
paper. 
 
Author response:  
The format/structure of the manuscript is changed so that it does not look like a 
report. An additional paragraph is added to address the reflections on the challenges 
the group has experienced during these years of comprehensive work. Also some 
practical examples are added (see lines 355 to 357).  
 
Revised content:  
See additional paragraph on reflections and challenges– lines 427 to 571 
 
 
Comment 2:  
The paper gives a comprehensive review of the tasks of the consortium. However, 
the language in the paper is rather heavy, several sections with sentences up to 50-
60 words. It is this reviewer's opinion that splitting sentences and using fewer words 
could significantly increase the readability of the paper. 
 
Responses to reviewers/editor
Author response:  
The manuscript is revised and simplified.  Long sentences are shorten.  
 
Comment 3:  
Table 1 should be restructured to not give the impression that the linings group 
different members. The different stakeholders should be listed consecutively within 
each category without apparently interlinking them. 
 
Author’response 
 Table 1 is removed as this information is available on EuPFI website. A reader can 
access the website to find the details on membership.  It has been replaced by 
general figure on EuPFI framework, which provides the EuPFI composition and 
working structure.  
 
 
Comment 4:  
References should be numbered in the text and the reference list revised to comply 
with the format instructions in the guide to authors. 
 
Authors response:  
References are cited as per Vancouver style as per the guide to authors. They are 
numbered consecutively in the order in which they are cited in the text. 
 
 
 
 
 
Reviewer #2:  
 
Comment 1:  
Abstract: 
Line 14: five different workstreams are mentioned: age appropriate medicines, 
biopharmaceutics, administration devices, excipients and taste assessment and taste 
masking. These workstreams are also mentioned on the EuPFi website, however on 
the website they are referred to as subgroups. 
 
Authors response:  
We have recently renovated our website. All the changes will reflected on updated 
website soon.  
 
Comment 2:  
On the website furthermore different names are used for the workstreams or work 
goups: Pharmaceutical excipients, taste masking and taste assessment methods, 
modification of dosage forms required for children (MDFRC), administration devices 
and age appropriateness of formulations. The use of different names for the 
workstreams (or work groups or subgroups) is confusing for the reader. I suggest 
uniformity in the use of the names. 
 
Author response:  
We have recently renovated our website. All the changes will reflected on updated 
website soon. The consistency in the names and terms used will be maintained.  
 
 
Comment 3:  
Introduction: 
A word is missing in line 8: off -patent paediatric medicines or formulations? 
 
Author response: 
Updated, included the word ‘medicines’ 
 
 
Comment 4: 
The main objective of the manuscript can be stated more clearly. I suggest to add a 
sentence containing the words 'an overview' in the title, abstract and introduction. 
 
Author response 
Updated, the term ‘Overview’ is added to title and abstract (line 18)  
 
 
 
Comment 4: 
Development of EuPFi: 
EMA has a role of an observer. Can you explain this in more detail, is EMA only an 
observer or may have influence on the objectives of EuPFi? 
 
Author reponse:  
The role of EMA is elaborated on lines 44 to 47.  
 
Text included :  
EMA acts as an observer to the group to observe proceedings/discussions in a 
passive way. They contribute to the exchange of comments and understanding of 
any recommendations raised by group members but does not influence the 
objectives of the EuPFI. 
 
 
Comment 5:  
Structure of EuPFI: 
Figure 1 is blurry 
 
Author response:  
Figure 1 is changed to another figure and higher version is provided.  
 
 
 
Comment 6:  
Age appropriate formulation workstream: 
Line 59: A reflection paper on…was published. Can you add more information about 
the content of this paper? 
 
Author response:  
Content added.  
 
Text included:  
The paper explores compounding and manipulation of medicines in relation to 
approval by medicines regulators to fulfil the needs of the individual patient. The 
team has proposed standardised definitions and terminology to clarify the types of 
paediatric pharmaceutical preparation. It aims to simplify strategies in product 
development to ensure quality and bioavailability 
 
Comment 7:  
 
Line 61- 63: Currently the workstream…acceptability assessment. Can you give some 
examples? For instance on pharmaceutical products. 
 
Author response:  
A systematic literature review is under construction on acceptability assessment 
methods used in paediatric formulations with the aim to provide an insight on 
standardising the methodology development. 
 
 
Comment 8:  
 
Biopharmaceutics: 
Line 78: Can you give examples of the in vitro tests used and what amendments are 
required? 
 
Author response:  
Sentence added:  
“Specifically research undertaken by the biopharmaceutics workstream to identify 
the relevant volume to classify a dose as highly soluble; values increased with age 
from a volume of 25 mL being  proposed for neonates compared to the adult volume 
of 250 mL. Dissolution conditions also suggested reduced volumes for younger 
children with <250mL for newborns and infants and larger volumes from 250-900mL 
for older children and adolescents” 
 
 
Comment 9:  
Line 84: You mention knowledge gaps in current methodologies, can you explain this 
in more detail? 
 
Sentence added:  
“Knowledge gaps identified included: better characterisation of the physiology and 
anatomy of the GI tract in paediatric patients; characterisation of age-specific 
changes in drug permeation across the intestinal membrane and the development of 
biorelevant media and testing conditions for dissolution”.  
  
 
 
Comment 10:  
 
Line 95: GI abbreviation. I suggest to use the full word. 
 
Author response:  
Agree. Amended the text.  
 
 
Comment 11:  
 
Administration devices: 
The first paragraph is very clear and well written! 
Line 113: You mention a survey which was conducted in six European countries. 
Which European countries were included in the survey? Is the healthcare system in 
these countries comparable? 
 
Author response:  
Sentence added :  
“The countries selected (UK, Italy, Spain, France, Hungary and Germany) were 
considered to represent the geographical and cultural diversity of Europe. The 
results provided some valuable insights indicating that HCPs are aware of patients 
and caregivers having difficulty in using these types of devices”.  
 
Comment 12:  
 
Line 116 - 117: caregivers have difficulty in using their devices. Was this applicable 
for all devices or just specific types of devices, since all devices need a different 
(tailor made) instruction and some devices are more user-friendly. 
 
Author response:  
This phrase relates to the results of the survey so re-phrased to “....caregivers having 
difficulty in using these types of devices.” 
 
 
Comment 13:  
 
Excipients: 
Line 129 -132: Some excipients…still developing. This is dependent on the 
administration route (differences in e.g., the oral or parenteral route). 
 
Author response:  
Amended as suggested.  
 
Revised text:  
Some excipients (e.g. propylene glycol, benzyl alcohol) are known to be less well 
tolerated by children depending upon the administration route, especially neonates 
and young children whose physiological system are still developing. 
 
Comment 14:  
 
Line 145 - 147: STEP database. Is the database updated on a regular basis? 
 
Author response: 
Sentence added: Existing data is updated regularly and additional excipients are 
added quarterly. 
 
Comment 15:  
Taste assessment & Taste Masking: 
Line 159 - 162: You mention the electronic tongue. Maybe out of the scope of this 
paper, but can you provide information about the applicability of the e-tongue 
(suitable for every API? How to interpret the results). 
 
Author response:  
Text added :  
Most of the published data reported good correlation between the human taste 
panel test and the electronic taste sensing systems. However, in most of these 
studies methods followed for bitterness prediction and constructing the correlation 
with human taste data were not always fully described. Electronic sensors give 
relative taste statement and should be validated with human taste panel tests. 
Ideally electronic tongues could be used for early screening of taste of pure APIs and 
optimisation of taste masked preclinical formulations in industry. 
However until it is demonstrated that electronic tongues can reliably predict 
bitterness intensity of the compounds, which were not used for developing 
calibration model, the use of this technology is still limited. 
 
 
Comment 16:  
Collaboration with other networks: 
This paragraph is quite unclear and confusing to me as a reader. Many names and 
abbreviations are used. I suggest a table (combine with table 1?) with the names and 
the tasks of the different networks. 
 
Author response:  
The paragraph on collaboration with network is deleted and the content in included 
elsewhere in the text as per the context and connected to the tasks.  
 
 
 
Line 178: use the full word in the text and GrIP enclosed by brackets 
 
Author response:  
Its abbreviation used by the network and hence is used in the text. Also it is spelled 
out on line 191 when it was used first time.  
 
Comment 17:  
Specific comments and typos: 
Line 94: exampler should be corrected to example 
 
Author response :  
exampler added.   
 
Comment 17:  
 
Line 236: FDA: why is the abbreviation underlined? 
 
Author response : Typo error, it is corrected.  
 
Table 1: EuPFI Objectives 
Table Captions
Table 1: EuPFI objectives 
Identify the issues and challenges associated with development of paediatric 
formulation and consider ways towards better medications and clinically relevant 
dosage forms for children. 
Promote early pharmaceutical consideration for development of paediatric 
medicines. 
Identify potential information, knowledge, know-how gaps in the paediatric 
formulation development. 
Improve the availability of information of paediatric formulations. 
 
 
Table 1
Figure 1:  EuPFI Framework 
Figure Captions
Figure1: EuPFI Framework 
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